• Johnson & Johnson Announces New Model for Data Transparency

    Xconomy | Johnson & Johnson today announced that an independent group at Yale will be empowered to review and grant scientific requests to see the full results of any clinical trial in the company's records.

    Jan 30, 2014
  • GenePeeks Readies Its In Silico Nursery

    Bio-IT World | GenePeeks, preparing to launch its service minimizing the risk of genetic disorders in children conceived through sperm donors, is awarded a patent for algorithms that create "digital children" from parental genotypes.

    Jan 30, 2014
  • Accelrys Acquired by Dassault Systemes for $750m

    Bio-IT World News Brief | Dassault Systèmes, a French company focused on Product Lifecycle Management (PLM), 3D design software and 3D digital Mock Up, announced its definitive agreement to acquire Accelrys last night in an all cash tender offer, representing a fully diluted equity value for Accelrys of approximately $750 million.

    Jan 30, 2014
  • Gene Therapy's Next Generation

    Bio-IT World | As a new generation of gene editing technologies like CRISPR and TALEN emerges, the founders of Editas Medicine think the time is right to forge ahead with gene therapy.

    Jan 29, 2014
  • Plotting the Discovery Curve: 33 New Cancer-Causing Mutations

    Bio-IT World | In a paper published in Nature last week, Broad researchers identified 33 new point mutations associated with cancer and estimated that mutations associated with at least 10% of cancer cases have been IDd. The next step is to find those mutations involved in only 5% or 2% of cancers.

    Jan 28, 2014
  • Getting to Know the New Reference Genome Assembly

    Bio-IT World | It's been almost five years since the Genome Reference Consortium released a brand-new assembly of the human reference genome. The NCBI's Valerie Schneider tells Bio-IT World what "build 38" brings to the table.

    Jan 27, 2014
  • Schizophrenia as a Spectrum

    Bio-IT World | Adding to the complex picture of schizophrenia's genetics is a recent study from Iceland, looking at those individuals who carry mutations that have been linked to schizophrenia – but who have not been diagnosed with the disorder.

    Jan 24, 2014
  • HP Launches Data Center Infrastructure Management Services

    Computerworld | HP is launching a suite of data center infrastructure management services based on the company's DCIM best practices that they call the Converged Management Framework.

    Jan 24, 2014
  • The Maddening Genetics of Schizophrenia

    Bio-IT World | The publication of the two largest genetic studies of schizophrenia ever undertaken points to several areas of the genome as key to understanding the disease. But the research also highlights just how difficult the genetics of this complicated disorder are to untangle.

    Jan 22, 2014
  • Appistry to Build Out, Support NIH Rare Disease Exome Pipeline

    Bio-IT World | The NIH’s Undiagnosed Diseases Program has turned their diploid aligner tool over to Appistry to make the pipeline “production-ready.” Appistry will host the tool in their cloud, and make the pipeline available to other users with commercial-grade support.

    Jan 22, 2014
  • JP Morgan and the Innovation Landscape

    Xconomy | Luke Timmerman sees a power shift in biotech and sums up last week's JP Morgan Healthcare Conference in one line: "It's the healthiest environment for innovation that I've seen in years."

    Jan 20, 2014
  • Acquired by IBM, Aspera Pushes On To the Science DMZ

    Bio-IT World | At Aspera, it’s business as usual, Michelle Munson told Bio-IT World this morning, after the announcement that the software company’s acquisition by IBM closed. Aspera’s software development is focused on continuing to increase raw performance; improving ease of use; integration; and developing its software developer kit and APIs.

    Jan 17, 2014
  • Catching Rare Disorders in the First Months of Life

    Bloomberg | A U.S. government-funded program is enabling hundreds of infants' genomes to be sequenced in medical centers around the country.

    Jan 16, 2014
  • FDA, 23andMe, and the Democratization of Healthcare

    Nature | Robert Green and Nita Farahany take on the FDA's treatment of 23andMe in a Nature comment today. "[R]egulatory constraints might stifle consumer genomics..." the two warned.

    Jan 15, 2014
  • Ingenuity to be Rebranded QIAGEN

    Bio-IT World News Brief | Since QIAGEN acquired Ingenuity Systems, Ingenuity has since been trading under the name QIAGEN Redwood City, but QIAGEN has announced that the company will now be branded as such as well.

    Jan 15, 2014
  • What You Need to Know About Illumina's New Sequencers

    Bio-IT World | Yesterday, Illumina announced the launch of the HiSeq X "thousand dollar genome" sequencer, and the world's first benchtop high-throughput sequencer, the NextSeq 500. Bio-IT World is here to catch you up on the details and examine the hype.

    Jan 15, 2014
  • Merck's Plans for Chemists, the FDA, and Upcoming Deals

    Forbes | Matthew Herper gets Merck on the phone to discuss strategy, the FDA, and organizational changes.

    Jan 15, 2014
  • Illumina Announces the Thousand Dollar Genome

    Bio-IT World News Brief | According to Illumina CEO Jay Flatley, the thousand dollar genome is finally here, with the new HiSeq X system already in production and ready to ship this March. The sequencer will be capable of delivering five whole human genomes a day at a cost of just under $1000 apiece.

    Jan 14, 2014
  • Regeneron Partners with Clinical Network on Large Genetic Study

    Bio-IT World News Brief | By partnering with Geisinger Health Systems in Pennsylvania, pharmaceutical developer Regeneron will get access to detailed electronic health records on the 100,000 volunteers it plans to sequence over the next five years.

    Jan 14, 2014
  • Wins and Deals at JP Morgan

    Xconomy | Luke Timmerman has a good roundup of the buzz and trends at the JP Morgan Healthcare Conference: deals, takeovers, and new target areas in biotech.

    Jan 13, 2014